LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in treatment resistant depression (TRD) during a virtual Capital Markets Day. The session, attended by members of COMPASS…


Previous articleClearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV
Next articleReunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference